New Alzheimer's Drug Shows Safer Brain Scan Results

Scientists may have found a way to treat Alzheimer's disease without the scary brain side effects that have worried patients and doctors.

ProMIS Neurosciences announced Tuesday that their experimental Alzheimer's drug caused brain bleeding in only 4.4% of patients during early clinical trials. Even better, not a single patient experienced brain swelling, the more serious complication that can occur with currently approved treatments.

The safety results matter because existing Alzheimer's drugs that target amyloid plaques in the brain often cause concerning side effects. These include ARIA-E, which causes brain swelling, and ARIA-H, which involves tiny bleeds in the brain.

In this trial, all the side effects were mild cases of ARIA-H, and patients didn't even notice symptoms. No one needed to stop treatment because of safety concerns.

Current Alzheimer's treatments like Leqembi and Aduhelm have helped slow cognitive decline, but their side effects have made many patients and families nervous. Some people have experienced serious brain swelling requiring hospitalization.

The Bright Side

This early data suggests scientists are getting closer to treatments that can fight Alzheimer's without forcing patients to choose between slowing their disease and risking dangerous brain complications.

The trial is still ongoing, and researchers haven't yet released data on whether the drug actually slows memory loss and cognitive decline. But the safety profile alone represents meaningful progress in a field where families have waited decades for better options.

More than 6 million Americans live with Alzheimer's disease, and that number continues to grow as the population ages. Each new treatment option brings hope to families watching loved ones slip away.

ProMIS will continue monitoring patients and expects to release effectiveness data later this year. If the drug proves both safe and effective, it could join a growing toolkit of treatments that finally give doctors real options for fighting this devastating disease.

For now, the safety results offer something families desperately need: hope that safer Alzheimer's treatments are within reach.